Deutsche Bank AG boosted its holdings in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 42.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 81,266 shares of the biotechnology company's stock after purchasing an additional 24,197 shares during the quarter. Deutsche Bank AG owned about 0.10% of Veracyte worth $3,218,000 at the end of the most recent quarter.
Several other hedge funds have also made changes to their positions in VCYT. Barclays PLC lifted its stake in Veracyte by 138.6% in the 3rd quarter. Barclays PLC now owns 146,402 shares of the biotechnology company's stock valued at $4,983,000 after buying an additional 85,033 shares in the last quarter. Legal Advantage Investments Inc. acquired a new stake in shares of Veracyte during the fourth quarter valued at $250,000. KBC Group NV boosted its stake in shares of Veracyte by 44.6% during the 4th quarter. KBC Group NV now owns 3,872 shares of the biotechnology company's stock worth $153,000 after purchasing an additional 1,195 shares during the last quarter. Baader Bank Aktiengesellschaft acquired a new position in shares of Veracyte in the fourth quarter valued at approximately $262,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in Veracyte by 11.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,433 shares of the biotechnology company's stock worth $651,000 after acquiring an additional 1,660 shares during the last quarter.
Analysts Set New Price Targets
A number of brokerages recently weighed in on VCYT. Craig Hallum assumed coverage on shares of Veracyte in a research report on Thursday, March 20th. They set a "buy" rating and a $45.00 target price for the company. Needham & Company LLC decreased their price target on shares of Veracyte from $51.00 to $41.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Guggenheim cut their price objective on Veracyte from $45.00 to $37.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Wall Street Zen cut Veracyte from a "buy" rating to a "hold" rating in a research note on Wednesday, February 26th. Finally, UBS Group dropped their target price on Veracyte from $49.00 to $42.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, Veracyte presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.90.
Check Out Our Latest Report on Veracyte
Veracyte Trading Down 0.9%
VCYT traded down $0.24 on Monday, reaching $27.16. The company had a trading volume of 612,390 shares, compared to its average volume of 894,629. Veracyte, Inc. has a one year low of $19.73 and a one year high of $47.32. The company has a market capitalization of $2.13 billion, a P/E ratio of -181.07 and a beta of 2.14. The company has a fifty day moving average of $30.39 and a 200-day moving average of $36.64.
Veracyte (NASDAQ:VCYT - Get Free Report) last announced its earnings results on Monday, February 24th. The biotechnology company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.07. Veracyte had a positive return on equity of 3.02% and a negative net margin of 2.18%. The business had revenue of $118.63 million during the quarter, compared to analysts' expectations of $110.73 million. During the same quarter last year, the business posted ($0.39) earnings per share. Research analysts predict that Veracyte, Inc. will post 0.68 EPS for the current year.
About Veracyte
(
Free Report)
Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.
Recommended Stories
Before you consider Veracyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veracyte wasn't on the list.
While Veracyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
